ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)
Current Status: Closed
Phase: III
Principal Investigator: Beck, Jill
Eligibility: https://clinicaltrials.gov/study/NCT02176967?term=NCT02176967&rank=1
Summary
The purpose of this study is to eliminate therapy as the initial approach for infants < 12 months of age with small INRG Stage L1 neuroblastoma while maintaining an overall survival (OS) of 99%. To eliminate therapy as the initial approach for non-high-risk patients < 18 months of age with localized neuroblastoma and favorable biology (histologic and genomic features) while maintaining an OS of 99%. To achieve a 3-year OS of > 81% for infants < 18 months of age with INRG Stage Ms neuroblastoma using objective criteria for early initiation of a response-based treatment algorithm.